HeartFlow
HTFL · NASDAQ · Healthcare
$50.75
+$1.21 (+2.38%) today
Market Cap
$4.41B
24h Volume
$335.2M
P/E Ratio
0.0
52w High
$50.75
52w Low
$20.49
Est. AI Revenue
100%
7-Day Sparkline (Static)
Company facts
Performance
About HeartFlow
HeartFlow uses AI to diagnose heart disease from standard CT scans. The company's software builds a personalized 3D model of a patient's coronary arteries and computes how blood flows through them, giving cardiologists answers that once required invasive catheterization. It earns revenue from per case analysis fees billed when clinicians order its tests.
Its product line covers the FFRct Analysis for blood flow assessment, Plaque Analysis for AI measured plaque burden, and Roadmap Analysis for coronary anatomy, together forming a precision coronary care platform used across hospital networks in the United States and internationally.
Founded in 2007 out of research at Stanford, HeartFlow is headquartered in San Francisco, employs around 840 people, and trades on the NASDAQ. Its technology is supported by clinical guidelines and a growing body of published outcome studies.
HeartFlow in the AI buildout
HeartFlow sits in the AI Healthcare layer, where trained models generate revenue directly as diagnostic output. Each analysis is inference: a CT scan goes in, an AI computed physiologic assessment comes out, and HeartFlow bills for it. That makes the company a clean test of AI economics in medicine, with automation replacing manual processing over time. The thesis depends on reimbursement, guideline adoption, and clinician trust rather than on AI infrastructure spending.
HTFL is tracked in AI Healthcare, rated Pure Play on the AI Exposure leaderboard.
By the numbers
52-week range
HTFL trades at $50.75, 100% of the way up its 52-week range of $20.49 to $50.75.
Market cap
Market capitalization is $4.41B, with an AI Exposure Score of 94 out of 100.
Next earnings
HeartFlow is next expected to report earnings on November 11, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does HeartFlow do?
HeartFlow analyzes coronary CT scans with AI to diagnose coronary artery disease. Its software constructs a 3D model of a patient's arteries and simulates blood flow, helping cardiologists decide whether a patient needs intervention without an invasive diagnostic procedure. Hospitals pay per analysis.
How is HeartFlow exposed to AI?
Entirely. Revenue comes from fees for AI generated analyses, and the product could not exist without its models. Supercycle rates it Pure Play with an AI Exposure Score of 94 out of 100, among the clearest medical AI pure plays on public markets.
Is HTFL a pure play AI stock?
Yes. Every product, FFRct Analysis, Plaque Analysis, and Roadmap Analysis, is the direct output of AI models applied to imaging data. There is no hardware, device, or non-AI service line, placing HeartFlow firmly in Supercycle's Pure Play tier.
What is FFRct?
FFRct stands for fractional flow reserve derived from CT. HeartFlow's software computes this measure of how severely a blockage limits blood flow, using computational fluid dynamics and AI on a standard CT scan, a value that previously required a pressure wire inside the artery.
Who leads HeartFlow?
John Farquhar serves as chief executive. The company was founded in 2007 out of Stanford research by Charles Taylor and John Stevens, who developed the computational modeling of coronary blood flow that became the company's diagnostic platform.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.